title: Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?
abstract: As reimbursement authorities are gaining greater power to influence the prescription behavior of physicians, it remains critical for life science companies focusing on personalized medicine to develop "tailor-made" payer engagement strategies to secure reimbursement and assure timely patient access to their innovative products. Depending on the types of such engagement, pharmaceutical and diagnostic companies may benefit by obtaining access to medical and pharmacy claims data, getting invaluable upfront inputs on evidence requirements and clinical trial design, and strengthening trust by payers, therefore avoiding uncertainties with regards to pricing, reimbursement, and research and development reinvestment. This article aims to study the evolving trend of partnering among two interdependent, yet confronting, stakeholder groups-payers and producers-as well as to identify the most promising payer engagement strategies based on cocreation of value introduced by life science companies in the past few years. We analyzed the recent case studies from both therapeutic and diagnostic realms considered as the "best practices" in payer engagement. The last 5 years were a breakout period for deals between life science companies and reimbursement authorities in the area of personalized medicine with a number of felicitous collaborative practices established already, and many more yet to emerge. We suggest that there are many ways for producers and payers to collaborate throughout the product life cycle-from data exchange and scientific counseling to research collaboration aimed at reducing healthcare costs, addressing adherence issues, and diminishing risks associated with future launches.
  
  
  
  The presented case studies provide clear insights on how successful personalized medicine companies customize their state-of-the-art payer engagement strategies to ensure closer proximity with payers and establish longer-term trust-based relationships.
authors.affiliation: Strategic Market Intelligence Department, Unicorn, P.O. Box 91, Zhytomyr, 10020 Ukraine.
authors.forename: Ildar
authors.initials: I
authors.lastname: Akhmetov
authors.affiliation: Clinical Hospital "Pheophania" of State Affairs Department, Zabolotny Str., 21, Kyiv, 03680 Ukraine ; 0000 0004 0385 8977grid.418751.eZabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Zabolotny Str., 154, Kyiv, 03680 Ukraine.
authors.forename: Rostyslav V
authors.initials: RV
authors.lastname: Bubnov
keywords: Market access; Payer engagement strategy; Predictive preventive personalized medicine; Reimbursement; Value creation